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5.1
A ROLE FOR A20 IN  TUMOUR ANGIOGENESIS
HW Chng 1, R Camplejohn 1, I Hart 2, L Nicholson 1
1 King’s College London, London, United Kingdom, 2 Tumour Biology 
Laboratory, Cancer Research UK, London, United Kingdom
The purpose of this study was to determine the role of A20 in angiogenic 
development.  A20 was identiﬁ  ed ﬁ  rst as an immediate-early, tumour 
necrosis factor (TNF)-responsive gene with an unique zinc ﬁ  nger motif. 
Being an anti-apoptotic molecule, A20 has been shown to inhibit TNF-
induced programmed death of human breast carcinoma cells (MCF 7), 
murine ﬁ  brosarcoma cells (WEHI 164), murine embryonic ﬁ  broblasts 
(NIH 3T3) and human umbilical vein endothelial cells (HUVECs). 
A20 also can inhibit apoptosis induced by other stimuli; including 
serum depletion of Louckes B cells, BJAB B cells and HUVECs, p53 
expression in H1299 epithelial cells, and LPS treatment of human 
microvascular endothelial HMEC-1 cells.  Our results from an in 
situ hybridisation assay on breast cancer tissue sections showed that 
expression of A20 was localised mainly to endothelium of tumour-
associated blood vessels. These preliminary data suggested a novel role 
for A20 in cancer angiogenesis. Accordingly we decided to use a small 
RNA interference assay (sRNAi) to downregulate the expression of 
A20 in HUVECs and assess how this downregulated expression of A20 
might inﬂ  uence tubule formation using an in vitro angiogenesis assay.   
We have conﬁ  rmed that downregulated expression of A20 in HUVECs 
was achieved at both the protein and RNA levels by Western blot 
analysis (50% protein [as determined by densitometry] for A20 RNAi 
cells versus 100% for scrambled RNAi treated at 48 hours time-point) 
and quantitative Real-Time PCR (transcript levels reduced by 50% after 
RNAi treatment) respectively.  More recently, in three independent 
experiments, we have shown this downregulated expression of A20 
reduces the number of tubules (3.3 versus 4.0, p0.01) and tubule 
length (1.4 versus 1.6, p0.01) in the in vitro angiogenesis kit. These 
initial results appear to indicate an exciting and important new role for 
A20 in promoting tumour angiogenesis, possibly through mediating 
improved survival of endothelial cells.
5.2
THERAPEUTIC EVALUATION OF THE VEGF RECEPTOR 
TYROSINE KINASE INHIBITOR ZD6474 IN A MURINE MODEL 
OF SPONTANEOUS COLORECTAL CANCER
RW Wilkinson 1, AJ Ryan 1, SR Wedge 1, ITG Pyrah 2, N Mandir 2,
RA Goodlad 2
1 AstraZeneca, Macclesﬁ  eld, United Kingdom, 2 Cancer Research UK, 
London, United Kingdom
ZD6474 is an orally active inhibitor of vascular endothelial growth factor
receptor-2 (VEGFR-2, KDR) tyrosine kinase activity, with additional
activity against epidermal growth factor receptor (EGFR) tyrosine kinase.
This study set out to examine the therapeutic effect of ZD6474 on early
colorectal tumourigenesis in multiple intestinal neoplasia (Min) mice. These
mice spontaneously develop numerous benign polyps due to a mutation of
the adenomatous polyposis coli (APC) gene, as in familial APC in humans.
ZD6474 (12.5, 25 or 50 mg/kg/day, p.o.) or vehicle was administered to 6-
week old Min mice (n=12) for 28 days. At autopsy, the small intestines and
colons were isolated, rinsed, weighed, dissected longitudinally, spread onto
ﬁ  lter paper, ﬁ  xed in Carnoy’s ﬁ  xative for 3 hours and then stored in 70%
ethanol. They were later assessed under a stereomicroscope for polyp number
and diameter. Tumour burden was calculated as the product of polyp number
and polyp volume. Additional satellite groups of mice (n=4) were taken for
histological examination and immunohistochemistry (IHC).
In the small bowel, ZD6474 (50 mg/kg/day) was associated with a signiﬁ  cant 
reduction both in mean polyp number per mouse (90.9 ± 20.7 vs 49.5 ± 12.9 in 
control vs treated, respectively, P=0.033) and in mean polyp diameter (1.18 ± 0.04 
mm vs 0.95 ± 0.05 mm, P=0.005), resulting in a 75% decrease in polyp burden 
(76.5 ± 11.7 mm3 vs 18.3 ± 5.6 mm3, P=0.005). In addition, ZD6474 (50 mg/kg/
day) treatment also resulted in fewer polyps in the colon (mean polyp number 3.46 
± 0.98 vs 0.83 ± 0.34 in control and treated, respectively, P=0.019). 
This activity is likely to be a consequence of inhibiting VEGF/VEGFR-
2 signalling during the early stages of tumour initiation and growth.
Immunostaining with an antibody for von Willebrand Factor (vWF) to label
vasculature, revealed strong staining in large polyps near the luminal surface.
ZD6474 signiﬁ  cantly reduces polyp growth and number in the Min mouse
model of intestinal adenoma, and provides a scientiﬁ  c rationale for studying
the effects of VEGFR-2 signalling inhibitors in early disease in the clinic.
ZD6474 is currently in Phase II clinical development.
5.3
ACUTE ANTI-VASCULAR EFFECTS OF COMBRETASTATIN A4 
PHOSPHATE (CA-4-P) ON THE SW1222 TUMOUR AS MEASURED 
BY DYNAMIC CONTRAST ENHANCED (DCE)-MRI
KJ Lankester 1, RJ Maxwell 1, RB Pedley 2, SA Hill 1, GJS Rustin 3, 
GM Tozer 1
1 Gray Cancer Institute, Northwood, Middlesex, United Kingdom, 2 
Dept of Oncology, Royal Free Hospital, London, United Kingdom, 
3 Dept of Medical Oncology, Mount Vernon Hospital, Northwood, 
Middleesex, United Kingdom
CA-4-P (200mg/kg) plus radioimmunotherapy (with anti-CEA antibody, 
131I-A5B7) can cure SW1222 tumours (human colon carcinoma xenograft) in 
mice. A phase I trial of this regimen has started with DCE-MRI to measure the 
acute anti-vascular effects of CA-4-P (using tissue uptake of contrast agent, 
Gd-DTPA). We used DCE-MRI to measure SW1222 response to CA-4-P at 
30mg/kg (clinically relevant dose), 100mg/kg and 200mg/kg in order to aid 
trial results. 
MF1 nude mice with SW1222 tumours implanted subcutaneously were 
treated with either saline (control) or 30, 100 or 200 mg/kg of   CA-4-P 
i.p. then imaged 4 or 24 hours post-injection. Tumour IAUGC (initial area 
under the Gd-DTPA concentration-time curve) was measured. The effect of 
CA-4-P on 131I-A5B7 retention in tumour 96 hours after injection was also 
determined.
All doses caused reduction in tumour 4 hours after CA-4-P injection (38%, 
71% and 86% decrease vs control for 30, 100 and 200mg/kg respectively, all 
p<0.05). At 24 hours, recovery was seen at 30mg/kg but reduction in IAUGC 
persisted at 100mg/kg (not signiﬁ  cant) and at 200mg/kg (58% decrease, 
p<0.05). Correlation coefﬁ  cients for dose-response were -0.88 (p<0.0001) 
and –0.59 (p<0.01) at 4 and 24 hours. Spatial heterogeneity was seen with 
a signiﬁ  cant difference between tumour centre and rim in baseline IAUGC 
and in response to CA-4-P at 100 & 200mg/kg at 4 hours. The magnitude 
in reduction of IAUGC at 30 mg/kg was similar to that seen in patients with 
CA-4-P (dose ≥52mg/m2). Antibody retention was signiﬁ  cantly increased vs 
control for all dose levels (by 71%, 78%, and 90% for 30, 100 and 200mg/kg 
respectively). Results show that low (clinically relevant) doses of     CA-4-P 
effectively enhance antibody retention despite only transient vascular effects.
Funding: Cancer Research UK, Marie Curie Translational Research Trust, 
Cancer Treatment and Research Trust.
5.4
TUMOUR MICROVASCULATURE ASSESSMENT BY DYNAMIC 
CONTRAST-ENHANCED MRI FAILS TO CORRELATE WITH 
VEGF EXPRESSION IN BREAST CANCER BIOPSIES
MW Ah-See 1, AR Padhani 1, NJ Taylor 1, FM Daley 2, SM Bentzen 2, 
RJ Burcombe 1, M Harrison 1, JJ Stirling 1, MO Leach 3, A Makris 1
1 Mount Vernon Hospital, Northwood, United Kingdom, 2 Gray Cancer 
Institute, Northwood, United Kingdom, 3 Royal Marsden Hospital, 
Sutton, United Kingdom
Background: Vascular endothelial growth factor (VEGF) is the principal
angiogenic factor driving neovascularisation within breast cancers. Multi-
functional dynamic contrast-enhanced MRI (DCE-MRI) provides a method
for assessing tumour microvasculature. Here we test the possible correlation
between tumour vascularity parameters as assessed by DCE-MRI & VEGF
expression in breast tumour biopsies.
Materials and Methods: 20 patients with biopsy-proven primary breast
cancer (median age 44 years, range 29-58) were imaged prior to treatment.
DCE-MRI was performed using gadolinium & parametric images were
calculated reﬂ  ecting microvessel permeability (Ktrans, ve, MaxGd), perfusion
(rBV , rBF, MTT) & oxygenation (R2*). Median values for each parameter were
derived from whole tumour regions of interest. The expression of VEGF in
the diagnostic biopsies was analysed by immunohistochemistry using the anti-
VEGF monoclonal antibody JH121 (Neomarker). The intensity & percentage
of VEGF staining was scored & a VEGF immunoreactive score was calculated
as the product of the 2 factors. The association between 2 parameters was
quantiﬁ   ed by Spearman’s rank correlation coefﬁ  cient,  rs, & the statistical
signiﬁ  cance was the 2-tailed P-value for rejecting the null hypothesis.
Results: Ktrans & R2* correlated signiﬁ  cantly with the perfusion parameters rBF
(rs =0.60, p<0.01 & rs =-0.68, p<0.01 respectively) & rBV (rs = 0.55, p<0.05 &
rs =-0.67, p<0.01 respectively). The median VEGF immunoreactive score was
6 (range 1-12). No correlation was found between tumour VEGF expression &
the pre-treatment vascular parameter values as assessed by DCE-MRI.
Conclusions: A strong correlation was demonstrated between the DCE-
MRI-derived vascular parameters reﬂ  ecting tumour microvessel permeability,
perfusion and oxygenation. No signiﬁ   cant correlation was seen between
tumour VEGF expression & DCE-MRI-derived vascular parameters, which
may be due to small patient number within the study or disparity between
visible & functional tumour microvasculature.
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VEGF, VEGF RECEPTORS AND ANGIOGENESIS IN 
HAPATOCELLULAR CARCINOMA
Z Gao 1, YL Zhu 2, B Wang 2, DX Yu 2
1 Department of Medical Biology, Weifang Medical University, 
Weifang, China, 2 Department of Radiology, Weifang, China
Introduction  To evaluate the expression of vascular endothelial growth 
factor (VEGF) and its receptors in the angiogenesis of HCC. 
Materials and Methods Thirty-nine cases (41 lesions) of HCC were proved 
surgically. Clinicopathological characteristics were analysed. The expressions 
of VEGF, Flt-1 and KDR/Flk-1 were detected with immunohistochemical 
SP method. The clinical and histopathological characteristics of HCC 
were compared with the immunohistochemical results of VEGF, Flt-1 and 
KDR/Flk-1. 
Results  The diameter was equal to or smaller than 5 cm in 22 lesions 
(22/41, 53.7%), the diameter was larger than 5 cm in 19 lesions (19/41, 
46.3%); pseudocapsula were found in 12 lesions (12/41, 29.3%), incomplete 
pseudocapsula or non-pseudocapsula were found in 29 lesions (29/41, 
70.7%). There were 11 lesions (11/41, 26.8%) in high potential invasion 
and metastasis group (intrahepatic daughter foci, tumor-emboli in portal 
veins, lymphaden metastasis), the others were 30 lesions (30/41, 73.2%) in 
low potential invasion and metastasis group. 32 lesions (32/41, 78.0%) were 
accompanied by hepatic cirrhosis and the others (9/41, 22.0%) were not. 
Immunohistochemical results showed that the positive rate of VEGF, Flt-1 
and KDR/Flk-1 expression was 61.0% (25/41), 68.3% (28/41) and 70.7% 
(29/41) respectively. VEGF and KDR/Flk-1 expression were signiﬁ  cantly 
different between the group of high potential invasion and metastasis 
and low potential invasion and metastasis (P < 0.05), the group of HCC 
with incomplete pseudocapsula or without pseudocapsula and complete 
pseudocapsula (P < 0.01), and the group of lesions whose diameter equal to 
or smaller than 5 cm and larger than 5 cm (P < 0.05). It showed that VEGF 
expression correlated with KDR/Flk-1 (P < 0.001). No correlations were 
found between Flt-1 and VEGF or KDR/Flk-1. 
Conclusions  These results suggest that VEGF and KDR/Flk-1 play a 
potential important role in the angiogenesis, growth and metastasis of HCC. 
5.6
TARGETING THE VASCULATURE – A NEW THERAPUETIC 
STRATEGY FOR DELAYING THE GROWTH OF EWING’S 
SARCOMA FAMILY OF TUMOURS (ESFT)
S Dalal 1, C Cullinane 2, S.A. Burchill 1
1 United Kingdom, Cancer Research UK Clinical Centre, St. James’s 
University Hospital, Leeds, 2 United Kingdom, Department of 
Pathology, St. James’s University Hospital, Leeds
Vascular endothelial growth factor (VEGF) and placental growth factor
(PlGF) are the key regulators of angiogenesis in ESFT (Dalal et al., 2003,
AACR, 44:3047), thus making them attractive targets for new therapeutic
strategies in this tumour group. In this study the effects of anti-VEGF
compounds rhuMAb-VEGF (Bevacizumab) and VEGF Trap, anti-receptor
tyrosine kinase compounds SU6668 and SU5416 and anti-vascular agents
combretastatin CA4, CA4 phosphate prodrug (CA4P) and ZD6126 on the
growth of subcutaneous (sc) ESFT in mice have been studied. Mice were
injected in a single sc site on the ﬂ  ank with ESFT RD-ES cells (5x106).
On day 15, mice were injected ip/sc with rhuMAb-VEGF (10mg/kg/x2
or x4/week; n=7-8), VEGF Trap (2.5 or 25mg/kg/x2/wk; n=5), SU6668
(100mg/kg/day; n=10), SU5416 (25mg/kg/day; n=10), CA4/CA4P (50mg/
kg/day; n=7) or ZD6126 (100mg/kg/day; n=8). Tumour size was measured
twice weekly. Once tumours reached 1.4cm2 or at a ﬁ  xed time point, mice
were sacriﬁ  ced, tumours excised, ﬁ  xed and embedded in parafﬁ  n. Histology
of tumours was examined by light microscopy after staining sections with
H&E. Treatment with rhuMAb-VEGF, VEGF Trap, SU6668 and SU5416
signiﬁ  cantly delayed tumour growth (p<0.001 for all groups), the efﬁ  cacy
of which was not dependent on initial tumour size. However, x4/week
rhuMAb-VEGF was not more effective than x2/week rhuMAb-VEGF.
Histology of treated tumours revealed geographical necrosis and reduced
vascularisation compared to untreated groups. Initial tumour growth was
also delayed following treatment with CA4, CA4P and ZD6126, with these
agents having a striking effect on tumour histology. All treated tumours
displayed large central areas of necrosis with no viable cells, however a
peripheral rim of viable proliferating tumour cells surrounded this.
Further studies are underway to fully investigate the activity of these
compounds in ESFT.
5.7
EFFECTS OF VARIOUS HEPARIN FRACTIONS OF DIFFERING 
MOLECULAR COMPOSITION ON PRIMARY TUMOUR 
GROWTH, ANGIOGENESIS AND APOPTOSIS IN A HEPARIN 
DEFICIENT TRANSGENIC MOUSE MODEL
F A Nasir 1, H K Patel 2, A K Kakkar 1
1 Department of Surgical Oncology and Technology, Imperial College, 
London, United Kingdom, 2 Thrombosis Research Institute, London, 
United Kingdom
Low molecular weight heparin therapy (LMWH) prolongs survival in patients 
with solid tumour malignancy.  The mechanism in unclear but is independent 
of the prevention of fatal thromboembolic events. We have studied the effects 
of various heparin fractions of differing molecular composition on primary 
tumour growth, angiogenesis and apoptosis in a heparin deﬁ  cient transgenic 
mouse model.
Mice deﬁ   cient by gene knockout, for the enzyme N-deacytylase/N-
sulphotransferase (NDST-2) and unable to synthesize cellular heparin, were 
injected subcutaneously in the ﬂ  ank with 2x106 B16/F10 murine melanoma 
cells, and randomly allocated to receive N/saline (n=36) Unfractionated heparin 
UFH (150 ug) (n=21), LMWH dalteparin(50 ug) (n-23) or Pentasaccharide 
(PS)(10ug) (n=21).  Tumour volumes were measured daily to day 15 to assess 
tumour growth and parafﬁ  n embedded sections of tumours was evaluated for 
apoptosis (TUNEL assay) and angiogenesis (after immunostaining with Anti-
CD 31 to count microvessels per high powered ﬁ  eld).  Differences among 
groups were analysed using a one-way analysis of variance and individual 
comparison against using control using the Dunnet test.
Control uFH PS LMWH
Tumour Vol/ mean ± SE
P vs control
108 ± 9  84 ± 11
n.s
72 ± 12
0.03
61 ± 9
0.002
Microvessel density/ hpf
P vs control
24 ± 2.9 20 ± 2.9
n.s
13 ± 3
0.02
12 ± 2.6
0.008
Apoptotic index (%)
P vs control
3.8 ± 03 4.7 ± 0.6
n.s
6.4 ± 0.5
n.s
11.3 ± 1.5
0.0001
These data indicate that the LMWH dalteparin is able to inhibit tumour growth 
through inhibition of angiogenesis and induction of apoptosis, and suggest 
a mechanism requiring more than just the inhibition of blood coagulation 
activation, through the inhibition of factor Xa, for its ability to induce these 
two powerful anti-tumour mechanisms.
5.8
DIFFERENTIATION MODULATES THE HYPOXIA-INDUCIBLE
GENE PROGRAM IN MACROPHAGES: EFFECTS OF 
ALTERATIONS IN IRON HOMEOSTASIS
HJ Knowles 1, PJ Ratcliffe 2, AL Harris 1
1 Cancer Research UK, Molecular Oncology Laboratory, Weatherall 
Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, 
United Kingdom, 2 The Henry Wellcome Building of Genomic 
Medicine, University of Oxford, Roosevelt Drive, Oxford, United 
Kingdom
Macrophage inﬁ  ltration into solid tumours is associated with poor prognosis,
tumour angiogenesis and high levels of VEGF. Hypoxia attracts tumour-
associated macrophages (TAMs) into avascular areas, where they express the
hypoxia-inducible transcription factors HIF-1α and HIF-2α. However, the
additional presence of some HIF-positive TAMs in vascular (and presumably
well oxygenated) areas suggests that the HIF pathway in macrophages may
be regulated by factors other than hypoxia.
In vitro differentiation of monocytic cell lines (THP1, U937) with 16 nM
phorbol 12-myristate 13-acetate (PMA) caused upregulation of HIF-2α
mRNA as detected by ribonuclease protection assay (fold induction 5.64 ±
3.4, P < 0.01) and induced expression of both HIF-1α and HIF-2α protein.
Both proteins were further inducible by hypoxia (16 h 0.1% O2). Presence
of differentiation-induced HIF was not due to altered expression of the
HIF-regulating PHD enzymes (PHD 1-3). However, this HIF was non-
hydroxylated and both 25 µM ascorbate and 50 µM FeCl2 antagonised its
induction by PMA-differentiation under normoxia, suggesting that PHD
enzyme activity is sub-maximal in differentiated cells. This may be due to
the reduced total iron content in differentiated macrophages compared with
monocytic cells (52.3% ± 27.4% iron as measured by ferrozine colorimetric
assay, P < 0.05). We have also analysed changes in the intracellular labile iron
pool using the ﬂ  uorescent iron chelator calcein-AM. We have investigated the
expression of iron-regulatory proteins during differentiation (e.g. transferrin
receptor, Nramp1) and their association with induction of HIF-α.
These data point to a clear change in the regulation of hypoxia-inducible
gene expression in macrophages, involving modulation of HIF and altered
iron homeostasis. This may be an adaptation of macrophages to prolonged
hypoxic exposure in solid tumour tissue.
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